Faculty Perspectives: Rationale for PD-L1 Expression as a Biomarker in Immuno-Oncology | Part 2 of a 4-Part Series


Rationale for PD-L1 Expression as a Biomarker in Immuno-Oncology

Therapy with immune checkpoint inhibitors (ICIs) heralds a new era in the management of many cancers. In particular, immunotherapy directed toward cytotoxic T-lymphocyte–associated antigen 4 and the programmed-cell death-1 (PD-1) receptor and its ligand, PD-L1, has demonstrated remarkable and durable responses in several types of cancer, including melanoma, non–small-cell lung [ Read More ]

The Evolving Role of PD-L1 Testing in Patients with Cancer

Clearly, immunotherapy has come of age in multiple tumor types, as described in the main article in this publication. The question now is how to develop more personalized immunotherapy and use biomarkers to identify patients most likely to benefit from this therapy. To benefit from immunotherapy, a patient’s tumor should [ Read More ]

Roy S. Herbst, MD, PhD

Ensuring Consistent and Reliable Biomarker Testing

In the main article of this publication, the current state of programmed-cell death-1 and programmed-cell death ligand-1 (PD-L1) testing, evasion by tumors of the immune system, and the study and use of immune checkpoint inhibitors across multiple tumor types are expertly summarized. Because this area of oncology is undergoing massive [ Read More ]

Harris S. Goodman, MD